Yes, You Can Split Your Weekly Methotrexate Dose
Yes, splitting your weekly methotrexate dose for rheumatoid arthritis into two doses taken 8 hours apart is a conditionally recommended strategy, particularly if you're experiencing tolerability issues with a single weekly dose. 1
Evidence-Based Recommendation
The 2021 American College of Rheumatology guideline explicitly supports this approach. A split dose of oral methotrexate over 24 hours is conditionally recommended over switching to alternative DMARDs for patients not tolerating oral weekly methotrexate. 1 While the certainty of evidence is very low, this strategy is preferred because it maintains the efficacy, long-term safety, and low cost advantages of methotrexate before abandoning it for other medications.
FDA Labeling Supports Multiple Dosing Schedules
The FDA-approved prescribing information for methotrexate in rheumatoid arthritis provides two distinct dosing schedules 2:
- Single oral dose: 7.5 mg once weekly
- Divided oral doses: 2.5 mg at 12-hour intervals for 3 doses given as a course once weekly
This FDA labeling confirms that split dosing is an established, approved administration method.
Pharmacokinetic Rationale
Split dosing actually improves methotrexate bioavailability at higher doses. Research demonstrates that when oral methotrexate doses exceed 15-20 mg weekly, absorption becomes saturated with single dosing. A pharmacokinetic study showed that splitting higher doses (25-35 mg) into two doses separated by 8 hours increased bioavailability by 28% compared to single dosing 3. The mean bioavailability improved from 0.76 to 0.90 compared to subcutaneous administration.
This occurs because methotrexate absorption is dose-dependent and becomes less efficient at higher single doses 2. Splitting the dose allows more complete absorption through the gastrointestinal tract.
Clinical Efficacy and Tolerability
Efficacy Outcomes
Multiple studies confirm that split dosing maintains equivalent efficacy:
- A 2018 randomized trial found that oral split doses (given 2-3 days apart) achieved similar low disease activity rates (49%) compared to single weekly oral doses (36%) and parenteral administration (47%) 4
- A 2002 study comparing twice-weekly versus once-weekly dosing found no significant difference in ACR 20 or ACR 50 response rates at both 8 and 16 weeks 5
Improved Side Effect Profile
Split dosing significantly reduces gastrointestinal side effects without compromising efficacy. A 2022 propensity-matched study of 246 patients demonstrated that alternate-day split dosing resulted in 6:
- Reduced gastritis: 63.4% vs 41.5%
- Reduced nausea: 51.2% vs 35.8%
- Reduced appetite loss: 74.0% vs 60.2%
- Reduced hepatotoxicity: 14.6% vs 5.7%
Practical Implementation
Dosing Schedule Options
- 8-hour split (same day): Take half your weekly dose, then the remaining half 8 hours later
- 12-hour split (FDA-approved): 2.5 mg doses at 12-hour intervals for 3 doses 2
- Alternate-day split: Divide weekly dose across 2-3 days of the week 4, 6
Important Caveats
- Patient education is critical: The most dangerous error is mistaking weekly dosing for daily dosing, which has led to fatal toxicity 2. Ensure you understand this is still a WEEKLY total dose, just divided.
- Prescriptions should not be written PRN 2
- Split dosing is most beneficial for doses ≥15 mg weekly, where single-dose absorption becomes limited 3
- Continue folic acid supplementation regardless of dosing schedule 1
When to Consider Split Dosing
Split dosing is particularly appropriate when:
- You're experiencing gastrointestinal side effects (nausea, decreased appetite, gastritis)
- Your weekly dose is ≥15 mg
- You want to optimize bioavailability before escalating to subcutaneous administration
- You're not achieving adequate disease control on standard once-weekly dosing
Monitoring Requirements
Regardless of dosing schedule, maintain standard monitoring 2:
- Complete blood count with differential: at least monthly
- Liver function tests: every 1-2 months
- Renal function tests: every 1-2 months
The split dosing strategy allows you to maximize methotrexate's therapeutic potential while minimizing side effects, before considering more expensive biologic DMARDs or the inconvenience of subcutaneous injections.